2017 Cancer Research Grant Program
Pediatric Cancer Research- Immunology or Immunotherapy
CALL FOR LETTERS OF INTENT

PURPOSE OF AWARD:
The V Foundation is pleased to announce a new grant opportunity in pediatric cancer immunology or pediatric cancer immunotherapy. Advances in cancer immunology research have led to recent unprecedented successes of immunotherapy in the clinic. The Foundation is seeking proposals that will further advance knowledge on the mechanisms driving anti-cancer immunity, including work on tumor antigens, immune biomarkers and the tumor immune microenvironment which may have future translational value.

The V Foundation welcomes proposals of preclinical research/translational research that supports new approaches to immunotherapy and immune-prevention of cancer, specifically in pediatric cancer research. The Foundation is interested in various immunotherapy/ cancer immunology research questions as applied to pediatric cancer, including: biomarker research for stratification, biomarker validation research, combination of checkpoint inhibitors with vaccines. The V Foundation encourages cross disciplinary research, including expertise from other disciplines (for example: bioinformatics, computational scientists, or engineers) as applicable to the research. Grants will be awarded through the Translational Award grant mechanism.

V Foundation definition of a translational research project: Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 5 years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial. The Award is a three-year grant of $200,000 per year. A maximum of 10% indirect costs (within the award amount) are supported in the Award. NIH salary caps are observed.

APPLICANT ELIGIBILITY:
Grant applicants must be nominated by their Cancer Center Director. Nominated applicants who will lead the research team must meet all of the following criteria to be eligible to submit an application:

- The nominee must be nominated by their Cancer Center Director if the research institution is a cancer center. V Foundation does not review unsolicited applications.
- Applicant must be employed at a US non-profit research institution (e.g. 501c3, Section 170)
- By the Due Date of the Application, applicants who will lead this research team must have all the following:
  - Be scientists who hold a faculty position at their cancer research institution. Non- promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for Principal Investigator nomination to lead the Translational Research Team.
- Applicants must be either US Citizens or have a legal permit to work in the USA (either temporary or permanent).
LETTER OF INTENT:
Letters of Intent (not to exceed 2 pages; minimum font size 11) are due May 26, 2017 in a single PDF to winshipgrants@emory.edu. Please save the cover page as page one of your 2 page Letter of Intent. Page 2: Please list any Co-PIs or Collaborators, if applicable (First and last name with degrees, institution). Please list your specific aims. The LOI will serve to identify specific areas of expertise for reviewer selection so please include relevant key words.

TIMELINE:
Letter of Intent Due to Winship: 5:00 PM on Friday, May 26, 2017
Winship Announcement of Nominee Selection: Friday, June 2, 2017
Full Application Due to V Foundation: Saturday, July 15, 2017
V Foundation Review Process Completed: September 2017
Grants Awarded: September 30, 2017
Grant Start Date: November 1, 2017